Intravitreal Sirolimus as Therapeutic Approach to Uveitis

NCT01280669 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Never started due to sponsor decision

Conditions

Uveitis
Intermediate Uveitis
Posterior Uveitis
Panuveitis

Interventions

DRUG: Intravitreal injection 440mcg
DRUG: Intravitreal injection of sirolimus 880mcg

Sponsor

Stanford University

Collaborators

[object Object]